Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial [Clinical Sciences]
Conclusions—
Observed relative efficacy and safety of rivaroxaban versus warfarin were similar among patients within and outside East Asia. Rivaroxaban, 20 mg once daily, is an alternative to warfarin for stroke prevention in East Asians with nonvalvular atrial fibrillation.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00123456.
Source: Stroke - Category: Neurology Authors: Wong, K. S. L., Hu, D. Y., Oomman, A., Tan, R.-S., Patel, M. R., Singer, D. E., Breithardt, G., Mahaffey, K. W., Becker, R. C., Califf, R., Fox, K. A. A., Berkowitz, S. D., Hacke, W., Hankey, G. J., on behalf of The Executive Steering Committee and the RO Tags: Other anticoagulants, Embolic stroke, Anticoagulants Clinical Sciences Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Clinical Trials | Congestive Heart Failure | Coumadin | Epidemiology | Heart | Heart Attack | Heart Failure | Neurology | Stroke | Vitamins | Warfarin